论文部分内容阅读
[目的]探究慢性乙肝患者的治疗方案。[方法]选取2013年1月~2015年1月在我院接受治疗的128例慢性乙肝患者,随机分为实验组和对照组。对照组采用阿德福韦酯片治疗,实验组采用扶正化瘀胶囊联合阿德福韦酯片治疗。比较2组患者的治疗效果。[结果]治疗后,2组患者的丙氨酸氨基转移酶(ALT)、乙型肝炎病毒DNA(HBV-DNA)水平,实验组患者明显优于对照组,差异有统计学意义(P<0.05)。2组患者的CD40、CD86、CD11C、HBV-DNA阴性(DNA-)、树突状细胞(DCS)激活性和γ干扰素(IFN-γ)水平,实验组患者明显优于对照组,差异具有统计学意义(P<0.05)。实验组患者中有1例出现乏力,3例出现食欲不振,2例出现腹泻,不良反应症状明显少于对照组,差异具有统计学意义(P<0.05)。[结论]采用扶正化瘀胶囊联合阿德福韦酯片治疗方案治疗慢性乙肝患者的效果更好,而且不良反应发生率也较低。
[Objective] To explore the treatment of chronic hepatitis B patients. [Methods] A total of 128 chronic hepatitis B patients treated in our hospital from January 2013 to January 2015 were randomly divided into experimental group and control group. The control group was treated with adefovir dipivoxil, and the experimental group was treated with Fuzhenghuayu capsule combined with adefovir dipivoxil tablets. Compare the treatment effect of 2 groups of patients. [Results] After treatment, the levels of ALT and HBV-DNA in the two groups were significantly better than those in the control group (P <0.05) ). The levels of CD40, CD86, CD11C, DNA-negative, DCS and IFN-γ in the two groups were significantly higher than those in the control group Statistical significance (P <0.05). One patient in experimental group had fatigue, three patients had loss of appetite, two patients developed diarrhea, the symptoms of adverse reactions were significantly less than those in control group, with statistical significance (P <0.05). [Conclusion] The treatment of chronic hepatitis B by Fuzheng Huayu capsule combined with adefovir dipivoxil tablets is better and the incidence of adverse reactions is lower.